Advances in non-small-cell lung cancer over the past decade have resulted in new treatments with minimal toxic effects and dramatic clinical benefits. 2010 saw continued advancement in our understanding of the molecular genetics of lung cancer and of specific targeted inhibitors with remarkable clinical benefit in selected populations.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Precision medicine and the problem of structural injustice
Medicine, Health Care and Philosophy Open Access 25 May 2023
-
Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness
Cancer Cell International Open Access 20 June 2022
-
Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p
Cell Death & Disease Open Access 16 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).
Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121–128 (2010).
Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).
Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).
Takeuchi, K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143–3149 (2009).
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734–1739 (2010).
National Lung Screening Trial Research Team. The National Lung Screening Trial: Overview and Study Design. Radiology doi:10.1148/radiol.10091808.
Acknowledgements
The authors wish to acknowledge the Vanderbilt–Ingram Cancer Center for continued support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lovly, C., Carbone, D. One size does not fit all. Nat Rev Clin Oncol 8, 68–70 (2011). https://doi.org/10.1038/nrclinonc.2010.224
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.224
This article is cited by
-
circRNA-CPA4 Regulates Cell Proliferation and Apoptosis of Non-small Cell Lung Cancer via the miR-1183/PDPK1 Axis
Biochemical Genetics (2024)
-
Precision medicine and the problem of structural injustice
Medicine, Health Care and Philosophy (2023)
-
Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness
Cancer Cell International (2022)
-
ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer
Oncogene (2021)
-
MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2
Cellular & Molecular Biology Letters (2019)
